Mr. Ellberger has been a pharmaceutical/biotech industry executive for over 40 years. From 1975 to 1995, Mr. Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporate Development. From 1995 to 1999, Mr. Ellberger was an officer of W.R. Grace & Co., serving as interim Chief Executive Officer, Chief Financial Officer and Senior Vice President, Strategic Planning and Development.
Mr. Ellberger was a Board member and Senior Vice President of Powderject plc from 2000 to 2003 when it was acquired by Chiron. He served as Chairman of the Board of Omrix Biopharmaceuticals until its acquisition by Johnson & Johnson in 2008. Mr. Ellberger was a director of NeuroDerm, a NASDAQ-listed Israeli biotech company, until its acquisition by Mitsubishi Tanabe in 2016. Until recently, he was Chairman of the Board of Directors of Celldex Therapeutics.
From 2003 to 2012, he was Founding Partner of HVA, a consulting firm specializing in business development, product acquisition and licensing, and mergers and acquisitions for pharmaceutical, biotechnology, drug delivery, and medical device companies. Mr. Ellberger received a B.A. in Economics from Columbia College and a B.Sc. in Chemical Engineering from Columbia School of Engineering.